ASCO26 Highlights Bispecifics, ADCs, RAS Revolution, Prostate Breakthrough
New, from #ASCO26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer https://t.co/rJehfuYEK0 @ByJonGardner and @Lilah_Alvarado $RVMD $MRK $SMMT $JNJ
Blood DNA Test Can Spare Millions From Unnecessary Chemotherapy
The dream I pursued during my PhD in genomics was to use blood tests to determine whether patients would respond to extensive and expensive therapies before even starting them. We demonstrated this in autoimmune conditions and biological therapies. Now the same...
HARMONi-6 Issues Persist, Lik
After listening to the updated HARMONi-6 readout at #ASCO26 many of the original issues are still holding up and may worsen over time...
Standing Ovation for Daraxonrasib Survival Benefit at ASCO26
Incredible #ASCO26 moment. Dr. Brian Wolpin, presenter of the daraxonrasib study, received a standing ovation DURING his talk after he stated the survival benefit for PDAC patients. It was sustained. Cheering. I have never see anything like it in the...
New Pancreatic Cancer Drug Shows Survival Boost
People who don't follow cancer research often ask me why we haven't cured cancer. That perception masks a wonderful reality: We make amazing, stepwise progress every year, and the result is that many people live much longer today than they...
Bispecific T‑cell Engager Shows Promising Responses in Refractory
Just published @NatureMedicine and presented @ASCO Advanced, refractory solid cancers treated with a bispecific T cell engager (BiTE, Figure), Phase 1 trial, with or without Keytruda, in 61 patients. Some very favorable responses with "manageable safety profile" https://t.co/MkzQXY1psA
Ivonescimab Plus Chemo Yields 71% Response In
Akeso ph2 trial of ivonescimab + chemo in 1L MSS/pMMR colorectal cancer (incl KRASm & w/t). ORR 71% (32/48). Via David Berz #ASCO26 $SMMT https://t.co/i5NW6fpKAu
Tobevibart + Elebs
Vir’s tobevibart + elebsiran hit 65.9% undetectable HDV RNA at week 24 in the SOLSTICE trial. Big step toward a potential accelerated approval for hepatitis D. HepatitisD
Exercise and NAD+ Boost Safety and Function in Friedreich’s Ataxia
Safety and efficacy of individualised exercise and NAD+ precursor supplementation in patients with Friedreich's ataxia in the USA: a single-centre, 2 × 2 factorial, randomised controlled trial https://t.co/1Pll9b0d4q
Exercise Undoes Calorie Restriction’s Anti‑Metastatic Benefit
The antimetastatic effects of calorie restriction are negated by voluntary exercise in an aggressive breast cancer mouse model https://t.co/e4WJspZAgu
VA Launches MDMA Trial; Psilocybin Shows Fast, Lasting Relief
Veterans Affairs announces new MDMA clinical trial; Psilocybin’s antidepressant effects are both rapid and long-lasting https://t.co/T5eCTPW77O
HDAC9 Deletion Reverses Age‑Related Fat Cell Decline
Histone Deacetylase 9 Gene Deletion Ameliorates Aging-Related Adipose Tissue Senescence and Mitochondrial Dysfunction in Mice ...suggesting that targeting HDAC9 may be a promising strategy to maintain healthy adipose tissue during aging." https://t.co/pi1aXAEoeB https://t.co/IB1yUwCaGC
Eli Lilly’s Triple‑Play Acquisitions Accelerate Vaccine Portfolio
28May: How expansive is @EliLillyandCo's expansion into infectious disease vaccine development, reflected in its 'triple play' acquisitions of @CurevoVaccine, Vaccine Company, and LimmaTech Biologics? My latest for @GENbio: https://t.co/vMUPpoCgCo
AbbVie Acquires Imgen’s ADC After Jazz Passes
Remember Decnupaz (pivekimab sunirine, then coded IMGN632) was one of two Immunogen ADCs $JAZZ decided not to opt into c2020. $ABBV later bought $IMGN for Elahere.
Harvard Scientists Win Breakthrough Prize for Gene Therapy Triumphs
Five Harvard-affiliated scientists received the 2026 Breakthrough Prize in Life Sciences for pioneering discoveries in gene therapy, sickle cell disease, ALS, dementia, and inherited blindness treatments. Their work helped advance groundbreaking therapies including the first FDA-approved treatment for a genetic disease,...